Scientists launch deep dive into rare liver disease PSC
NCT ID NCT04685200
First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 17 times
Summary
This study aims to understand what causes primary sclerosing cholangitis (PSC), a rare chronic liver disease. About 143 adults with PSC will provide blood, saliva, urine, stool, and tissue samples, plus undergo imaging and procedures like colonoscopy and liver biopsy. No treatment is given; the goal is to gather data to uncover the disease's biological roots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 143 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
40 male and female adult patients 18 years of age or above with known PSC recruited from hospitals in the continental US. 90 healthy volunteers, male and female 18 years of age or above, who are either family members of participating patients with PSC or have been cohabitating with participating patients with PSC.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* PSC SUBJECTS: INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Male or nonpregnant female, greater than or equal to 18 years of age 3. Evidence of PSC established by biochemical testing and either MRCP or ERCP. Participant must have evidence of large duct disease on imaging. 4. Agreement to adhere to Lifestyle Considerations throughout study duration. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Pregnant or lactating women or females of child-bearing age not taking measures to prevent pregnancy during the period of study. 2. History of clinical, serologic, or histopathologic evidence supporting etiologies of chronic liver disease other than PSC 3. History of liver transplantation 4. Diagnosis consistent with secondary sclerosing cholangitis (cholelithiasis, bile duct strictures secondary to ischemia, HIV cholangiopathy, etc.). 5. Current or past clinical evidence of decompensated liver disease (e.g. ascites, bleeding esophageal varices, spontaneous bacterial peritonitis, encephalopathy, etc.). 6. History of liver or bile duct lesions concerning for malignancy. 7. Ca-19-9 \>130 U/microL 8. Alpha-fetoprotein level greater than 200 ng/microL. 9. Patients with active bacterial, viral, or fungal, systemic or localized infection. 10. Unwillingness to refrain from ingesting probiotics during study. 11. History of systemic disease not related to PSC that is poorly controlled or associated with declining functional status. Examples include but are not limited to: poorly controlled diabetes mellitus, chronic renal failure with eGFR is \<60 microl/min/1.73m\^2, chronic symptomatic heart failure or severe COPD. 12. Patients with history of any gastrointestinal malignancy in the last 3 years prior to enrollment will be excluded. Patients with history of any malignancy in the last 3 years prior to enrollment other than those individuals who had undergone curative surgical therapy and deemed as low risk for recurrence by her/his treating physician would be excluded. 13. History of portal vein thrombosis 14. Patients with severe allergic reactions to iodine or other contrast, which cannot be controlled by premedication with antihistamines or steroids. 15. History of gastric and/or proximal small bowel surgery including bariatric surgery such as Roux-en-Y gastric bypass 16. Contraindication to monitored anesthesia care and/or medications that are commonly used for conscious sedation during GI Endoscopy 17. Use of anti-coagulant and anti-platelet agents excluding aspirin and NSAIDs 18. Contraindications to completing MRCP or MRI 19. Absolute neutrophil count below 1000/mm\^3 20. Hemoglobin level below 10.0 g/dl 21. Platelet count lower than 50,000/mm\^3. 22. INR greater than or equal to 1.5, PTT greater thna or equal to 1.3 times control and/or any known history of disease associated with increased bleeding diathesis. 23. Inability to provide informed consent CONTROLS: INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Male or female greater than or equal to 18 years of age 2. Any individual who is either a parent, sibling or child of a PSC patient enrolled to the study, or an unrelated person who has been living with the patient for at least 3 consecutive months before study enrollment EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. History suggestive of PSC 2. History of chronic liver disease (except for steatosis) 3. Patients with history of any malignancy in the 3 years prior to enrollment other than those individuals who had undergone curative surgical therapy and deemed as low risk for recurrence by her/his treating physician would be excluded. 4. History of Inflammatory Bowel Disease 5. Antibiotic use within the last 6 weeks 6. Pregnancy 7. Inability to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary sclerosing cholangitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a shared data network transform care for kids with liver disease?
- Could a simple MRI spare young patients from invasive liver biopsies?
- MRI as a crystal ball for young liver disease patients?
- Can a new drug outperform standard care for a rare liver disease in teens?
- Could a new molecule tame a rare liver disease? early safety trial begins
- Blood test may tame the tightrope walk of transplant drugs